Inclusion Criteria:
1. Adult patients (at least 18 years of age at time of treatment decision)
- Diagnosis of SCCHN and patients are progressing on or after platinum-based
therapy
- Diagnosis of SCCHN has been confirmed by histology or cytology (either at initial
diagnosis or any time later during the course of the disease)
- Treatment decision to initiate a treatment with nivolumab for the first time for
the treatment of SCCHN (according to the label approved in Germany) has already
been taken
2. Patients who provided informed consent to participate in the study
Exclusion Criteria:
1. Patients with a current primary diagnosis of a cancer other than SCCHN, ie, a cancer
other than SCCHN that requires systemic or other treatment, or has not been treated
curatively (as per discretion of the investigator)
2. Patients previously treated with nivolumab and/or ipilimumab, an anti-PD-1,
anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug
specifically targeting T-cell co-stimulation or immune checkpoint pathways (applicable
for any indication)
3. Patients currently included in an interventional clinical trial for their SCCHN.
Patients who have completed their participation in an interventional trial; or who are
not receiving study drug anymore and who are only followed-up for OS can be enrolled
Activo, no reclutando
